Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc.
Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it had completed its acquisition of United States company Angioblast Systems Inc with the issue of 90.8 million ordinary shares to former Angioblast security holders, increasing the total number of shares on offer to 253.8 million shares. Notably, no former Angioblast security holders elected to take a cash entitlement, resulting in a total saving to Mesoblast of approximately A$47 million.
China Bio-Agriculture Industry Summit 2011 will be convened in Shanghai China on February 24-25, 2011. It is committed to providing a comprehensive picture of policy support, market trends, multi-national cooperation in R&D and technical innovations and investment climate of the industry.
Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that, following the clarification provided by the re-examination decision for the landmark United States Patent 6,573,099 in RNA interference, it has reviewed the claim scope of the pending US applications with its US attorney and has determined a strategy for the continued prosecution of these applications to maximise their benefits, as presaged in the announcement regarding the R&D Pipeline and Strategy on 3 September 2010.
Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to announce that the European Patent Office has issued a Communication of Intent to Grant on application 2005 727 680 "Multiple promoter expression cassettes for simultaneous delivery of RNAi agents".
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) and global biopharmaceutical company, Cephalon, Inc. (NASDAQ:CEPH), today announced they have entered into a strategic alliance to develop and commercialize novel adult stem cell therapeutics for degenerative conditions of the central nervous and cardiovascular systems. These conditions include Parkinson's disease, Alzheimer's Disease, Congestive Heart Failure and Acute Myocardial Infarction. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
Mesoblast Limited (ASX:MSB) (PINK:MBLTY) is pleased to release Chairman's address 2010 Annual General Meeting.
